Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein

S. Snitkovsky, T. M.J. Niederman, R. C. Mulligan, J. A.T. Young

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Previously, we have demonstrated that bridge proteins comprised of avian leukosis virus (ALV) receptors fused to epidermal growth factor (EGF) can be used to selectively target retroviral vectors with ALV envelope proteins to cells expressing EGF receptors. To determine whether another type of ligand incorporated into an ALV receptor-containing bridge protein can also function to target retroviral infection, the TVA-VEGF110 bridge protein was generated. TVA-VEGF110 consists of the extracellular domain of the TVA receptor for ALV subgroup A (ALV-A), fused via a proline-rich linker peptide to a 110-amino-acid form of vascular endothelial growth factor (VEGF). This bridge protein bound specifically to its cell surface receptor, VEGFR-2, and efficiently mediated the entry of an ALV-A vector into cells. These studies indicate that ALV receptor-ligand bridge proteins may be generally useful tools for retroviral targeting approaches.

Original languageEnglish (US)
Pages (from-to)1571-1575
Number of pages5
JournalJournal of virology
Issue number3
StatePublished - 2001
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Insect Science
  • Virology


Dive into the research topics of 'Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein'. Together they form a unique fingerprint.

Cite this